Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Nicholas J. Vogelzang Stories

2013-10-02 16:24:44

TEANECK, N.J., Oct. 2, 2013 /PRNewswire/ -- Holy Name Medical Center's Cancer Center announces today the introduction of Xofigo® (radium 223 dichloride) for the treatment of select patients with advanced prostate cancer. Holy Name is the only Bergen county facility offering this break through treatment. In May, the U.S. Food and Drug Administration (FDA) approved Xofigo(®) (radium Ra 223 dichloride) for the treatment of patients with bone metastasis who have hormone-resistant...

2013-09-25 11:02:09

Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone. The study, published Sept. 24 in Lancet Oncology, was led by Ethan Basch, MD, director of the Cancer Outcomes Research Program at the University of North Carolina Lineberger Comprehensive Cancer Center. Researchers measured the pain and quality of life...

2013-09-20 08:25:10

WHIPPANY, N.J., Sept. 20, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use (CHMP) recommended Xofigo(®) (radium Ra 223 dichloride) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases. The decision of the European Commission on the approval is expected in the second half of 2013. Xofigo...

2013-09-18 12:30:51

AUSTIN, Texas, Sept. 18, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced today its collaboration with US Oncology Research to conduct a pivotal Phase III Trial for colorectal cancer. Through the collaboration, US Oncology Research will leverage its national network of affiliated oncology centers to treat patients with XBiotech's new anti-cancer therapy and report clinical outcomes. Patients enrolled in the trial will receive at least the current...

2013-07-17 16:28:17

WHIPPANY, N.J., July 17, 2013 /PRNewswire/ -- Bayer HealthCare today announced that data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial of its drug Xofigo(®) (radium Ra 223 dichloride) in castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases and no known visceral metastatic disease are published in the July 18 issue of the New England Journal of Medicine (NEJM). These data supported the U.S. Food and Drug...

2013-07-10 12:28:06

"Oncology Protocol Challenge" and New Appointments Underscore Commitment to Cancer Studies ROCKVILLE, Md., July 10, 2013 /PRNewswire-USNewswire/ -- This spring has seen Accelovance, a Rockville, Md. Clinical Research Organization (CRO) serving biotech and small and mid-sized pharmaceutical companies, advance its goal of providing premier services within oncology clinical research. The company successfully completed its first-ever "Oncology Protocol Challenge" at the American...

2013-05-29 08:30:11

~New indication provides physicians with option to be used earlier in treatment of the disease, with hope of delaying chemotherapy~ TORONTO, May 29, 2013 /CNW/ - Janssen Inc. announced today that Health Canada has approved the once-daily, oral medication ZYTIGA(®) (abiraterone acetate), for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who are asymptomatic or mildly symptomatic after failure of androgen...

2013-05-23 12:27:26

Study to evaluate whether drug works better against tumors with specific genetic anomaly ANN ARBOR, Mich., May 23, 2013 /PRNewswire-USNewswire/ -- Are certain drugs more effective against some types of prostate cancers than others? Researchers know that not all therapies work for all patients - the next question is to figure out how to match the right treatments with the right patients. A new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to...

2013-05-15 12:34:17

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved Xofigo(®) (radium Ra 223 dichloride) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Xofigo is the first and only alpha particle-emitting radioactive therapeutic agent approved by the FDA that has demonstrated...

2013-04-10 23:02:57

ACF Welcomes Prominent Veterinary and Human Oncologists to its Scientific Advisory Council. The Council Advises the Executive Board on Comparative Oncology Award Grant Criteria and Evaluation. Norwalk, Connecticut (PRWEB) April 10, 2013 Animal Cancer Foundation (ACF) has appointed several prominent leaders in the veterinary and human oncology field to serve as Scientific Advisory Council to its Executive Board. (http://www.acfoundation.org/about/council.php) The Scientific Advisory...